hydroxychloroquine has been researched along with Branch Retinal Artery Occlusion in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 5.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
| "A patient in her late 50s with antiphospholipid syndrome presented to general ophthalmology clinic for annual hydroxychloroquine retinopathy screening." | 4.12 | Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate. ( Baxter, SL; Delavar, A, 2022) |
| "Antiphospholipid syndrome is a rare cause of ocular vaso-occlusive disease, but is associated with significant systemic morbidity and mortality." | 2.48 | Antiphospholipid antibody syndrome. ( Foster, CS; Kruh, JN; Yang, P, 2012) |
| "Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 1.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ameen Ismail, A | 1 |
| Sadek, SH | 1 |
| Hatata, RM | 1 |
| Delavar, A | 3 |
| Baxter, SL | 3 |
| Ebrahimiadib, N | 1 |
| Riazi-Esfahani, H | 1 |
| Heidari, M | 1 |
| Mahmoudi, A | 1 |
| Yang, P | 1 |
| Kruh, JN | 1 |
| Foster, CS | 1 |
1 review available for hydroxychloroquine and Branch Retinal Artery Occlusion
| Article | Year |
|---|---|
Antiphospholipid antibody syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Humans; Hyd | 2012 |
3 other studies available for hydroxychloroquine and Branch Retinal Artery Occlusion
| Article | Year |
|---|---|
Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
Topics: Adult; Antirheumatic Agents; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Ocular flare-up in patients with systemic lupus erythematosus following discontinuation of hydroxychloroquine.
Topics: Aged; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Middle Aged; Retinal | 2020 |